Side-by-side · Research reference
DermorphinvsLL-37
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED20/47 cited
BHuman-MechanisticHUMAN-REVIEWED15/35 cited
Dermorphin
Opioid Peptide · μ-Receptor Agonist · Research Only
Research only · ICV / SC (animal models)
LL-37
Cathelicidin · Human AMP
Broad-spectrumAntimicrobial activity
Endogenous · Secreted at inflammation sites
01Mechanism of Action
Parameter
Dermorphin
LL-37
Primary target
μ-opioid receptors (central and peripheral)Negri 1992Steel 2014
Pathway
μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization
hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption
Downstream effect
Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects
Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026Zhang 2026
Feedback intact?
N/A — exogenous opioid agonist
—
Origin
Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998Mignogna 1992
Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)
02Dosage Protocols
Parameter
Dermorphin
LL-37
Legal status
Controlled substance in many jurisdictions · Research only
Not approved for human use.
—
Animal research (ICV)
Low nanomolar to picomolar range
Intracerebroventricular administration in rodent models.
—
Detection limit (doping)
5 pg/mL in equine plasma/urineSteel 2014
High-throughput LC-MS/MS screen developed for racing industry.
—
Duration of action
10–120 minutes (dose-dependent, intrathecal)
—
Evidence basis
Animal studies · In vitro assays
In vitro, animal models, human observational
Human toxicity
Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025
—
Endogenous expression
—
Constitutive in neutrophils, epithelial tissues
Upregulated during infection and inflammation.Pinheiro 2026
Exogenous (experimental)
—
Dose varies by study; antimalarial ~10–50 μM in vitro
No FDA-approved exogenous formulation.
04Side Effects & Safety
Parameter
Dermorphin
LL-37
Opioid effects
Respiratory depression, sedation, euphoria, tolerance, dependence risk
—
Kambô ritual toxicity
Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025
—
Receptor selectivity caveat
Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992
—
Proteolytic stability
Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996
—
Cytotoxicity (high dose)
—
Membrane disruption in host cells at supraphysiological concentrations
Pro-inflammatory signaling
—
Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026
Theoretical cancer risk
—
Immunomodulatory roles in tumor microenvironment under investigation
Absolute Contraindications
Dermorphin
- ·Human use — not approved by any regulatory authority
- ·Controlled substance status — possession illegal in many jurisdictions
- ·Known opioid hypersensitivity or respiratory compromise
LL-37
—Relative Contraindications
Dermorphin
- ·Any context outside approved animal research protocols
- ·CNS depressant co-administration
LL-37
- ·Active autoimmune disease (theoretical immune dysregulation)
05Administration Protocol
Parameter
Dermorphin
LL-37
1. Legal and ethical framework
Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.
LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.
2. Animal research protocols
In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.
Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.
3. Analytical detection
High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014
LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026
4. Kambô ritual (traditional use)
Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025
—